Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AS703569/gemcitabine · 1 trial · 1 indication
To determine the maximum tolerated dose (MTD) during a 21-day cycle, for each of the two planned regimens using combination therapy with AS703569 and gemcitabine.
| Arm | Type | Description |
|---|---|---|
| Regimen 1: AS703569/gemcitabine | EXPERIMENTAL | Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle |
| Regimen 2: AS703569/gemcitabine | EXPERIMENTAL | AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle |
| Name | Type | Description |
|---|---|---|
| AS703569/gemcitabine | DRUG | Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next. Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle. |
Inclusion Criteria: Histologically/cytologically confirmed diagnosis of measurable or assessable malignancy, who meets one of the following conditions: Subject with a tumour for which gemcitabine is approved, Subject with a tumour for which gemcitabine is considered standard of care, Subject with ...
Top 20 of 68 competitors
AS703569/gemcitabine is an investigational combination therapy being studied for the treatment of pancreatic cancer. It combines the small molecule AS703569 with the chemotherapy agent gemcitabine. The combination was evaluated in a Phase 1 clinical trial in patients with advanced malignancies, including pancreatic cancer.
AS703569/gemcitabine is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company sponsored a Phase 1 clinical trial of the combination therapy in patients with advanced malignancies, including pancreatic cancer.
AS703569/gemcitabine is in Phase 1 clinical development. A Phase 1 trial of the combination has been completed. The drug is investigational and has not been approved by regulatory authorities. It remains in early-stage clinical development for pancreatic cancer.
AS703569/gemcitabine was studied in one clinical trial, registered as NCT01097512, titled 'AS703569 and Gemcitabine Combination in Advanced Malignancies.' This Phase 1 study enrolled 66 participants with pancreatic cancer and was conducted in Belgium and France. The trial has been completed.
No, AS703569/gemcitabine is a combination therapy that includes gemcitabine plus the investigational small molecule AS703569. It is not the same as gemcitabine monotherapy. The combination was evaluated in a Phase 1 trial for advanced malignancies, including pancreatic cancer.